{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:20Z","timestamp":1793316260994,"version":"4.5.0"},"reference-count":305,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.phrs.2013.11.002","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T13:14:56Z","timestamp":1385039696000},"page":"34-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1247,"special_numbering":"C","title":["The ErbB\/HER family of protein-tyrosine kinases and cancer"],"prefix":"10.1016","volume":"79","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2013.11.002_bib0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0010","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/1097-0142(19830515)51:10<1787::AID-CNCR2820511004>3.0.CO;2-A","article-title":"The epidermal growth factor (EGF)","volume":"51","author":"Cohen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0015","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0020","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0021-9258(19)68224-4","article-title":"A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles","volume":"257","author":"Cohen","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0025","first-page":"767","article-title":"The EGF receptor: structure, regulation, and potential role in malignancy","volume":"4","author":"Thompson","year":"1985","journal-title":"Cancer Surv"},{"key":"10.1016\/j.phrs.2013.11.002_bib0030","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2004.05.018","article-title":"Protein tyrosine phosphatases in the human genome","volume":"117","author":"Alonso","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0040","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1006\/geno.2002.6748","article-title":"Guidelines for human gene nomenclature","volume":"79","author":"Wain","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2013.11.002_bib0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/geno.2002.6747","article-title":"Rules and guidelines for mouse gene, allele, and mutation nomenclature: a condensed version","volume":"79","author":"Maltais","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2013.11.002_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF00360651","article-title":"Standardized rat genetic nomenclature","volume":"6","author":"Levan","year":"1995","journal-title":"Mamm Genome"},{"key":"10.1016\/j.phrs.2013.11.002_bib0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0065","first-page":"1","article-title":"The neuregulin-I\/ErbB signaling system in development and disease","volume":"190","author":"Britsch","year":"2007","journal-title":"Adv Anat Embryol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0070","doi-asserted-by":"crossref","first-page":"H543","DOI":"10.1152\/ajpheart.91436.2007","article-title":"Cardiac ErbB-1\/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction","volume":"295","author":"Rajagopalan","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/376337a0","article-title":"Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor","volume":"376","author":"Miettinen","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0080","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1126\/science.7618084","article-title":"Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype","volume":"269","author":"Threadgill","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib0085","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/378390a0","article-title":"Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor","volume":"378","author":"Gassmann","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0095","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/39593","article-title":"Severe neuropathies in mice with targeted mutations in the ErbB3 receptor","volume":"389","author":"Riethmacher","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0100","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/309418a0","article-title":"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells","volume":"309","author":"Ullrich","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0105","doi-asserted-by":"crossref","first-page":"26761","DOI":"10.1074\/jbc.272.42.26761","article-title":"A novel juxtamembrane domain isoform of HER4\/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester","volume":"272","author":"Elenius","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0110","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/0008-5472.CAN-10-1872","article-title":"Trastuzumab has preferential activity against breast cancers driven by ERBB2 homodimers","volume":"71","author":"Ghosh","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0115","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1073\/pnas.1002753107","article-title":"ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0120","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0125","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.phrs.2013.11.002_bib0130","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"Pinkas-Kramarski","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.phrs.2013.11.002_bib0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1677\/erc.0.0080075","article-title":"The Type 1 growth factor receptors and their ligands considered as a complex system","volume":"8","author":"Gullick","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrm1548","article-title":"ADAMs: key components in EGFR signalling and development","volume":"6","author":"Blobel","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0145","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biochi.2007.08.008","article-title":"Emerging roles of ADAM and ADAMTS metalloproteinases in cancer","volume":"90","author":"Rocks","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.phrs.2013.11.002_bib0150","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.it.2011.05.005","article-title":"ADAM17: a molecular switch to control inflammation and tissue regeneration","volume":"32","author":"Scheller","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2013.01.012","article-title":"ADAM17, shedding, TACE as therapeutic targets","volume":"71","author":"Rose-John","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0160","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0092-8674(02)00966-2","article-title":"Ligand-induced, receptor-mediated dimerization and activation of EGF receptor","volume":"110","author":"Schlessinger","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/44394","article-title":"Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme","volume":"401","author":"Aritomi","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains","volume":"110","author":"Ogiso","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","article-title":"Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor \u03b1","volume":"110","author":"Garrett","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(03)00048-0","article-title":"The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors","volume":"11","author":"Garrett","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(03)00047-9","article-title":"EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization","volume":"11","author":"Ferguson","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0190","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1097-2765(03)00350-2","article-title":"An open-and-shut case? Recent insights into the activation of EGF\/ErbB receptors","volume":"12","author":"Burgess","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0195","doi-asserted-by":"crossref","first-page":"34913","DOI":"10.1074\/jbc.M102874200","article-title":"Crystal structure of human epidermal growth factor and its dimerization","volume":"276","author":"Lu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/08977190009003231","article-title":"Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor","volume":"18","author":"Domagala","year":"2000","journal-title":"Growth Factors"},{"key":"10.1016\/j.phrs.2013.11.002_bib0205","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1126\/science.1074611","article-title":"Structure of the extracellular region of HER3 reveals an interdomain tether","volume":"297","author":"Cho","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib0210","doi-asserted-by":"crossref","first-page":"15024","DOI":"10.1073\/pnas.0507591102","article-title":"The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand","volume":"102","author":"Bouyain","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0215","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0220","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1073\/pnas.1201114109","article-title":"A single ligand is sufficient to activate EGFR dimers","volume":"109","author":"Liu","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0225","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.cell.2010.07.015","article-title":"Structural basis for negative cooperativity in growth factor binding to an EGF receptor","volume":"142","author":"Alvarado","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0230","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.1074\/jbc.M113.489534","article-title":"Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging","volume":"288","author":"Macdonald-Obermann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0240","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos Trans R Soc Lond Biol Sci"},{"key":"10.1016\/j.phrs.2013.11.002_bib0245","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.3291115","article-title":"The protein kinase family: conserved features and deduced phylogeny of the catalytic domains","volume":"241","author":"Hanks","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib0255","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein kinase biochemistry and drug discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0260","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0265","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0270","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases: controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0275","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0006-291X(92)90812-Y","article-title":"A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor","volume":"186","author":"Gotoh","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.11.002_bib0280","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","article-title":"Mechanism of biological synergy between cellular Src and epidermal growth factor receptor","volume":"96","author":"Tice","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0285","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.91.17.8132","article-title":"Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity","volume":"91","author":"Guy","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0014-4827(02)00101-5","article-title":"The deaf and the dumb: the biology of ErbB-2 and ErbB-3","volume":"284","author":"Citri","year":"2003","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0295","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.tcb.2006.07.003","article-title":"Emerging roles of pseudokinases","volume":"16","author":"Boudeau","year":"2006","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0300","doi-asserted-by":"crossref","first-page":"13237","DOI":"10.1073\/pnas.1200105109","article-title":"Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.phrs.2013.11.002_bib0310","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0315","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.1074\/jbc.274.12.8335","article-title":"c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function","volume":"274","author":"Biscardi","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0320","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1073\/pnas.1111316109","article-title":"Mechanics of EGF receptor\/ErbB2 kinase activation revealed by luciferase fragment complementation imaging","volume":"109","author":"Macdonald-Obermann","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0330","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.molcel.2009.04.034","article-title":"The juxtamembrane region of the EGF receptor functions as an activation domain","volume":"34","author":"Red Brewer","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0335","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cell.2012.12.030","article-title":"Architecture and membrane interactions of the EGF receptor","volume":"152","author":"Arkhipov","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0340","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2009.04.025","article-title":"Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment","volume":"137","author":"Jura","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0345","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1073\/pnas.0708281105","article-title":"6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases","volume":"105","author":"Wood","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0350","doi-asserted-by":"crossref","first-page":"6950","DOI":"10.1074\/jbc.M709202200","article-title":"Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state","volume":"283","author":"Bocharov","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0355","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jmb.2010.05.016","article-title":"Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases","volume":"400","author":"Mineev","year":"2010","journal-title":"J Mol Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0360","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/pro.5560070423","article-title":"The dimerization motif of the glycophorin A transmembrane segment in membranes: importance of glycine residues","volume":"7","author":"Brosig","year":"1998","journal-title":"Protein Sci"},{"key":"10.1016\/j.phrs.2013.11.002_bib0365","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jmb.2009.04.002","article-title":"Two GxxxG-like motifs facilitate promiscuous interactions of the human ErbB transmembrane domains","volume":"389","author":"Escher","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0370","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1128\/MCB.00742-10","article-title":"Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor","volume":"30","author":"Lu","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0375","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cell.2012.12.032","article-title":"Conformational coupling across the plasma membrane in activation of the EGF receptor","volume":"152","author":"Endres","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nsmb.2221","article-title":"Finding the missing links in EGFR","volume":"19","author":"Bessman","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0385","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nature08827","article-title":"Spatial control of EGF receptor activation by reversible dimerization on living cells","volume":"464","author":"Chung","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib0390","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nsmb.2092","article-title":"Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor","volume":"18","author":"Mi","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0395","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jsb.2009.04.007","article-title":"Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics","volume":"167","author":"K\u00e4stner","year":"2009","journal-title":"J Struct Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0400","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0405","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.phrs.2013.11.002_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.11.008","article-title":"Functional selectivity of EGF family peptide growth factors: implications for cancer","volume":"122","author":"Wilson","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2013.11.002_bib0420","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0425","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0430","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.11.002_bib0435","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.11.002_bib0440","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0445","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(92)90167-B","article-title":"The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling","volume":"70","author":"Lowenstein","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0450","first-page":"947","article-title":"The SH2 and SH3 adapter Nck: a two-gene family and a linker between tyrosine kinases and multiple signaling networks","volume":"15","author":"Li","year":"2000","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0455","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nsmb1241","article-title":"Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK","volume":"14","author":"Kobashigawa","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0460","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1074\/jbc.M207555200","article-title":"Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac","volume":"278","author":"Tam\u00e1s","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0465","doi-asserted-by":"crossref","first-page":"30716","DOI":"10.1074\/jbc.M202823200","article-title":"Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation","volume":"277","author":"Xia","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0470","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0378-1119(02)00602-9","article-title":"The identification of a novel human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of highly conserved small proteins related to thioredoxin superfamily","volume":"291","author":"Mazzocco","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.phrs.2013.11.002_bib0475","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1349-7006.2007.00374.x","article-title":"Biomarker discovery: a proteomic approach for brain cancer profiling","volume":"98","author":"Khalil","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.phrs.2013.11.002_bib0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0485","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0898-6568(96)00135-0","article-title":"Ras-GTPase activating protein (GAP): a putative effector for Ras","volume":"9","author":"Tocque","year":"1997","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2013.11.002_bib0490","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein-tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.11.002_bib0495","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","article-title":"Structure and dynamic regulation of Abl kinases","volume":"288","author":"Panjarian","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0500","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/bcr261","article-title":"Syk: a new player in the field of breast cancer","volume":"3","author":"Stewart","year":"2001","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0505","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-physiol-030212-183750","article-title":"Mammalian phospholipase C","volume":"75","author":"Kadamur","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0510","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.phrs.2007.04.001","article-title":"Classical PKC isoforms in cancer","volume":"55","author":"Martiny-Baron","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0515","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1734-1140(11)70395-4","article-title":"Protein kinase C\u025b as a cancer marker and target for anticancer therapy","volume":"63","author":"Toto\u0144","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.phrs.2013.11.002_bib0520","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrd3871","article-title":"Protein kinase C, an elusive therapeutic target?","volume":"11","author":"Mochly-Rosen","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2013.11.002_bib0525","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.cellsig.2007.04.008","article-title":"Protein kinase C\u025b makes the life and death decision","volume":"19","author":"Basu","year":"2007","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2013.11.002_bib0530","first-page":"1507","article-title":"PKC\u03b7 is a novel prognostic marker in non-small cell lung cancer","volume":"32","author":"Krasnitsky","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0535","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/187152011794941154","article-title":"SHP-1 in cell-cycle regulation","volume":"11","author":"L\u00f3pez-Ruiz","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0540","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1074\/jbc.M210430200","article-title":"Crystal structure of human protein-tyrosine phosphatase SHP-1","volume":"278","author":"Yang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0545","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1078\/S0171-9335(04)70029-1","article-title":"Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1\/3 activation in A431 cells","volume":"79","author":"Tenev","year":"2000","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0550","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000276765","article-title":"Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors","volume":"77","author":"Insabato","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.phrs.2013.11.002_bib0555","doi-asserted-by":"crossref","first-page":"13952","DOI":"10.1074\/jbc.M210670200","article-title":"Development of an efficient substrate-trapping mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates","volume":"278","author":"Agazie","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0560","doi-asserted-by":"crossref","first-page":"12226","DOI":"10.1074\/jbc.M900020200","article-title":"Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation","volume":"284","author":"Zhou","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0565","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1073\/pnas.86.4.1168","article-title":"v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas","volume":"86","author":"Langdon","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0570","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1083\/jcb.200106056","article-title":"Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies","volume":"156","author":"Longva","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0575","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1091\/mbc.E07-10-0988","article-title":"Ubc4\/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation","volume":"19","author":"Umebayashi","year":"2008","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0580","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1242\/jcs.091280","article-title":"The role of ubiquitylation in receptor endocytosis and endosomal sorting","volume":"125","author":"Haglund","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1016\/j.phrs.2013.11.002_bib0585","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1083\/jcb.71.1.159","article-title":"125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts","volume":"71","author":"Carpenter","year":"1976","journal-title":"J Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0590","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/bies.950150603","article-title":"Endocytosis of growth factor receptors","volume":"15","author":"Sorkin","year":"1993","journal-title":"Bioessays"},{"key":"10.1016\/j.phrs.2013.11.002_bib0595","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1074\/jbc.271.9.5251","article-title":"All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired","volume":"271","author":"Baulida","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0600","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.yexcr.2008.09.027","article-title":"Trafficking of receptor tyrosine kinases to the nucleus","volume":"315","author":"Carpenter","year":"2009","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0605","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840130104","article-title":"Localization of epidermal growth factor receptor in hepatocyte nuclei","volume":"13","author":"Marti","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2013.11.002_bib0610","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1038\/onc.2010.157","article-title":"Nuclear trafficking of the epidermal growth factor receptor family membrane proteins","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2013.11.002_bib0615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrm1331","article-title":"Nucleocytoplasmic shuttling of signal transducers","volume":"5","author":"Xu","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0620","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-biochem-060109-151030","article-title":"The structure of the nuclear pore complex","volume":"80","author":"Hoelz","year":"2011","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0625","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrc3219","article-title":"The nuclear envelope environment and its cancer connections","volume":"12","author":"Chow","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0630","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/jcb.20876","article-title":"Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin \u03b21 and CRM1","volume":"98","author":"Lo","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0635","doi-asserted-by":"crossref","first-page":"11005","DOI":"10.1128\/MCB.25.24.11005-11018.2005","article-title":"Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor","volume":"25","author":"Giri","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0640","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.sbi.2010.09.008","article-title":"Recognition of nuclear targeting signals by Karyopherin-\u03b2 proteins","volume":"20","author":"Xu","year":"2010","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0645","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0962-8924(01)02144-4","article-title":"Nucleocytoplasmic transport: Ran, beta and beyond","volume":"11","author":"Kuersten","year":"2001","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0650","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.1074\/jbc.M610014200","article-title":"Characterization of a novel tripartite nuclear localization sequence in the EGFR family","volume":"282","author":"Hsu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0655","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1158\/1078-0432.CCR-08-2813","article-title":"Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors","volume":"15","author":"Wang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0660","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ncb0901-802","article-title":"Nuclear localization of EGF receptor and its potential new role as a transcription factor","volume":"3","author":"Lin","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0665","doi-asserted-by":"crossref","first-page":"e71518","DOI":"10.1371\/journal.pone.0071518","article-title":"Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3","volume":"8","author":"Brand","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2013.11.002_bib0670","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ijc.25743","article-title":"Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer","volume":"128","author":"Napoli","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0675","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cell.2006.07.037","article-title":"Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain","volume":"127","author":"Sardi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0680","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jnr.20381","article-title":"Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions","volume":"79","author":"Fox","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0685","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/onc.2009.234","article-title":"Nuclear EGFR contributes to acquired resistance to cetuximab","volume":"28","author":"Li","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2013.11.002_bib0690","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4161\/cbt.12.5.16394","article-title":"Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab","volume":"12","author":"Brand","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.phrs.2013.11.002_bib0695","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cell.2006.09.013","article-title":"Nuclear signaling by receptor tyrosine kinases: the first robin of spring","volume":"127","author":"Schlessinger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0700","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.phrs.2013.11.002_bib0705","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.phrs.2013.11.002_bib0710","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0715","first-page":"56","article-title":"Lung cancer: diagnosis and management","volume":"75","author":"Collins","year":"2007","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.phrs.2013.11.002_bib0720","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0725","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0730","series-title":"Cancer chemotherapy and biotherapy: principles and practice","year":"2011"},{"key":"10.1016\/j.phrs.2013.11.002_bib0735","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mds590","article-title":"Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"24","author":"Soria","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0740","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phrs.2010.03.005","article-title":"Targeting nanoparticles to cancer","volume":"62","author":"Wang","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0745","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMct0807960","article-title":"Treatment of non-small-cell lung cancer with erlotinib or gefitinib","volume":"364","author":"Cataldo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0750","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0755","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0169-5002(03)91900-3","article-title":"Gefitinib (Iressa, ZD 1839) monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone","volume":"41","author":"Bailey","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0760","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2013.11.002_bib0765","doi-asserted-by":"crossref","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2013.11.002_bib0770","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0775","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib0780","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0785","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"Massarelli","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0790","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0795","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0800","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0805","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0810","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib0815","series-title":"Enzyme kinetics and mechanism","first-page":"8","author":"Cook","year":"2007"},{"key":"10.1016\/j.phrs.2013.11.002_bib0820","doi-asserted-by":"crossref","first-page":"E3595","DOI":"10.1073\/pnas.1220050110","article-title":"Mechanism for activation of mutated epidermal growth factor receptors in lung cancer","volume":"110","author":"Red Brewer","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0825","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0006-2952(94)90042-6","article-title":"Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor","volume":"48","author":"Ward","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0830","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","article-title":"In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors","volume":"51","author":"Giard","year":"1973","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.phrs.2013.11.002_bib0835","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1021\/bi00266a011","article-title":"Adenosine cyclic 3\u2032,5\u2032-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit","volume":"21","author":"Cook","year":"1982","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2013.11.002_bib0840","doi-asserted-by":"crossref","first-page":"16788","DOI":"10.1021\/bi981291f","article-title":"Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis","volume":"37","author":"Parast","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2013.11.002_bib0845","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF01803785","article-title":"Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines","volume":"38","author":"Wakeling","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.phrs.2013.11.002_bib0850","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1021\/jm00018a008","volume":"38","author":"Rewcastle","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib0855","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2013.11.002_bib0860","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0865","first-page":"739","article-title":"Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice","volume":"291","author":"Pollack","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.11.002_bib0870","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2013.11.002_bib0875","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.11.002_bib0880","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1582-4934.2009.00991.x","article-title":"Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis","volume":"14","author":"Paz-Ares","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0885","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0890","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0895","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0900","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib0905","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.phrs.2013.11.002_bib0910","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0915","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc060020","article-title":"HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer","volume":"354","author":"Cappuzzo","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0920","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2012.01.008","article-title":"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2\/neu","volume":"76","author":"De Gr\u00e8ve","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0925","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(19840201)53:3+<630::AID-CNCR2820531308>3.0.CO;2-3","article-title":"Steroid-hormone receptors in breast cancer","volume":"53","author":"Wittliff","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib0930","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.phrs.2013.11.002_bib0935","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14656566.8.4.485","article-title":"Docetaxel\/anthracycline combinations for breast cancer treatment","volume":"8","author":"von Minckwitz","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.phrs.2013.11.002_bib0940","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2013.11.002_bib0945","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0950","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1185\/03007995.2012.707643","article-title":"Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC)","volume":"28","author":"Riemsma","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.phrs.2013.11.002_bib0955","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1158\/1078-0432.CCR-13-1038","article-title":"Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2","volume":"19","author":"Rexer","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0960","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2165\/11634000-000000000-00000","article-title":"Overcoming treatment resistance in HER2-positive breast cancer: potential strategies","volume":"72","author":"Puglisi","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2013.11.002_bib0965","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/MCB.9.3.1165","article-title":"p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor","volume":"9","author":"Hudziak","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0970","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib0975","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib0980","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/annonc\/mdq607","article-title":"Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?","volume":"22","author":"Verma","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0985","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90276-3","article-title":"Mechanism of action of trastuzumab and scientific update","volume":"28","author":"Baselga","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib0990","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib0995","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1126\/science.1241145","article-title":"Antibody therapeutics in cancer","volume":"341","author":"Sliwkowski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib1000","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1005","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1172\/JCI36049","article-title":"Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family","volume":"118","author":"Shepard","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2013.11.002_bib1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications","volume":"17","author":"Rexer","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.phrs.2013.11.002_bib1015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib1020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1025","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1158\/1078-0432.CCR-13-1212","article-title":"First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer","volume":"19","author":"Blumenthal","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","article-title":"Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth","volume":"2","author":"Agus","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib1035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00262-005-0058-x","article-title":"Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab","volume":"55","author":"Adams","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.phrs.2013.11.002_bib1040","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody\u2013cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1045","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1050","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","article-title":"Trastuzumab emtansine: a unique antibody\u2013drug conjugate in development for human epidermal growth factor receptor 2-positive cancer","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1055","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.phrs.2013.11.002_bib1065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbrc.2003.08.055","article-title":"STI-571: an anticancer protein-tyrosine kinase inhibitor","volume":"309","author":"Roskoski","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.11.002_bib1070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.11.002_bib1075","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.11.002_bib1080","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib1090","series-title":"The biology of cancer","first-page":"550","author":"Weinberg","year":"2014"},{"key":"10.1016\/j.phrs.2013.11.002_bib1095","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1100","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.phrs.2013.11.002_bib1110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2013.11.002_bib1115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nrclinonc.2010.166","article-title":"BRCA mutations in the management of breast cancer: the state of the art","volume":"7","author":"Narod","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1120","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1125","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-03-1061","article-title":"Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type","volume":"10","author":"Foulkes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1130","first-page":"333","article-title":"Towards the goal of personalized medicine in gastric cancer \u2013 time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification","volume":"15","author":"Lee","year":"2013","journal-title":"Discov Med"},{"issue":"2B","key":"10.1016\/j.phrs.2013.11.002_bib1135","first-page":"1213","article-title":"Chemotherapy in gastric cancer","volume":"28","author":"W\u00f6ll","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1140","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2013.11.002_bib1145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib1150","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1016\/S0021-9258(17)42857-2","article-title":"Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity","volume":"259","author":"Gill","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib1155","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model","volume":"1","author":"Goldstein","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1160","doi-asserted-by":"crossref","first-page":"27595","DOI":"10.1016\/S0021-9258(18)47026-3","article-title":"Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells","volume":"269","author":"Fan","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib1165","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1175","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1185","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2013.11.002_bib1200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","article-title":"First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer","volume":"138","author":"K\u00f6hne","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1205","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2013.11.002_bib1215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib1220","first-page":"49","article-title":"Critical appraisal of the use of regorafenib in the management of colorectal cancer","volume":"5","author":"Festino","year":"2013","journal-title":"Cancer Manage Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1225","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1230","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","article-title":"Structure and regulation of Kit protein-tyrosine kinase \u2013 the stem cell factor receptor","volume":"338","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.11.002_bib1235","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccr.2013.04.012","article-title":"Oncogenic ERBB3 mutations in human cancers","volume":"23","author":"Jaiswal","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib1240","first-page":"340","volume":"5","author":"No authors listed","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.phrs.2013.11.002_bib1245","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1634\/theoncologist.2012-0458","article-title":"Approval summary: cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer","volume":"18","author":"Cohen","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2013.11.002_bib1250","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/14728222.2011.607438","article-title":"Emerging pathways and future targets for the molecular therapy of pancreatic cancer","volume":"15","author":"Vaccaro","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.phrs.2013.11.002_bib1255","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1260","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fphar.2013.00056","article-title":"Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy","volume":"4","author":"Tamburrino","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1265","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2174\/138945012800564149","article-title":"Conventional chemotherapy of advanced pancreatic cancer","volume":"13","author":"Giuliani","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.phrs.2013.11.002_bib1270","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1275","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1280","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gtc.2011.12.004","article-title":"Pancreatic cancer: medical management (novel chemotherapeutics)","volume":"41","author":"P\u00e1ez","year":"2012","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.phrs.2013.11.002_bib1285","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/00006676-200407000-00061","article-title":"The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma","volume":"29","author":"Ueda","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.phrs.2013.11.002_bib1290","first-page":"777","article-title":"Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma","volume":"1","author":"Ng","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.phrs.2013.11.002_bib1295","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1300","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1305","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib1310","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1093\/nar\/16.16.7773","article-title":"KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas","volume":"16","author":"Smit","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0030-1255225","article-title":"Brain metastases","volume":"30","author":"Kamar","year":"2010","journal-title":"Semin Neurol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1325","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1330","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.nec.2012.05.002","article-title":"Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme","volume":"23","author":"Spasic","year":"2012","journal-title":"Neurosurg Clin N Am"},{"key":"10.1016\/j.phrs.2013.11.002_bib1335","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1593\/neo.10688","article-title":"Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance","volume":"12","author":"Hatanpaa","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2013.11.002_bib1340","first-page":"2164","article-title":"Genes for epidermal growth factor receptor, transforming growth factor \u03b1, and epidermal growth factor and their expression in human gliomas in vivo","volume":"51","author":"Ekstrand","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1345","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1073\/pnas.89.7.2965","article-title":"Structural alterations of the epidermal growth factor receptor gene in human gliomas","volume":"89","author":"Wong","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.11.002_bib1350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.phrs.2013.11.002_bib1355","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.phrs.2013.11.002_bib1360","first-page":"3","article-title":"The influence of lipophilicity in drug discovery and design","volume":"86","author":"Arnott","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.phrs.2013.11.002_bib1365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6468(09)04801-2","article-title":"Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design","volume":"48","author":"Smith","year":"2009","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.phrs.2013.11.002_bib1370","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1375","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2013.11.002_bib1380","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.drudis.2008.11.007","article-title":"Ligand efficiency and fragment-based drug discovery","volume":"14","author":"Bembenek","year":"2009","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.phrs.2013.11.002_bib1385","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0002-9610(63)90232-0","article-title":"The initial clinical trial of nitrogen mustard","volume":"105","author":"Gilman","year":"1963","journal-title":"Am J Surg"},{"key":"10.1016\/j.phrs.2013.11.002_bib1390","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1021\/tx970192k","article-title":"Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice","volume":"11","author":"He","year":"1998","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1395","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1039\/C2DT31833D","article-title":"Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems","volume":"42","author":"Sevrioukova","year":"2013","journal-title":"Dalton Trans"},{"key":"10.1016\/j.phrs.2013.11.002_bib1400","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2133\/dmpk.23.87","article-title":"Intestinal first-pass metabolism of CYP3A4 substrates","volume":"23","author":"Kato","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.phrs.2013.11.002_bib1405","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajcn\/83.5.1097","article-title":"A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice\u2013felodipine interaction","volume":"83","author":"Paine","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.phrs.2013.11.002_bib1410","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2125.2004.02095.x","article-title":"Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin","volume":"58","author":"Lilja","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1415","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.hoc.2011.03.004","article-title":"Biology of germ cell tumors","volume":"25","author":"Ma","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.phrs.2013.11.002_bib1420","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.1998.16.2.702","article-title":"Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience","volume":"16","author":"Saxman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1425","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"K\u00fcppers","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2013.11.002_bib1430","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/asheducation-2011.1.310","article-title":"Optimal therapy of advanced Hodgkin lymphoma","volume":"2011","author":"Advani","year":"2011","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.phrs.2013.11.002_bib1435","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.seminoncol.2008.12.009","article-title":"Management of gestational trophoblastic neoplasia","volume":"36","author":"Horowitz","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1440","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.hoc.2011.10.007","article-title":"Current management of gestational trophoblastic neoplasia","volume":"26","author":"Goldstein","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.phrs.2013.11.002_bib1445","first-page":"CD005196","article-title":"Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour","volume":"1","author":"Deng","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.phrs.2013.11.002_bib1450","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2008.21.2134","article-title":"Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening \u2013 a report from the American Society of Clinical Oncology","volume":"27","author":"Winer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1455","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.hoc.2011.09.006","article-title":"Selection of therapy: rational decisions based on molecular events","volume":"25","author":"Khorashad","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.phrs.2013.11.002_bib1460","series-title":"Cecil medicine","first-page":"1209","article-title":"The chronic leukemias","author":"Kantarjian","year":"2012"},{"key":"10.1016\/j.phrs.2013.11.002_bib1465","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.11.002_bib1470","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.11.002_bib1475","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.phrs.2010.01.013","article-title":"HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent implications in nanomedical approaches","volume":"62","author":"Colombo","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1480","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2013.11.002_bib1485","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression-implications for drug resistance","volume":"10","author":"Kuczynski","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1490","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/annonc\/mdh006","article-title":"Effect of re-treatment with gefitinib (\u2018Iressa\u2019, ZD1839) after acquisition of resistance","volume":"15","author":"Kurata","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1495","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3727\/096504005775082020","article-title":"Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases","volume":"15","author":"Yano","year":"2005","journal-title":"Oncol Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1500","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/JTO.0b013e318183afb0","article-title":"Lung cancer response to gefitinib, then erlotinib, then gefitinib again","volume":"3","author":"Wong","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1505","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2012.59","article-title":"Treatment selection in metastatic renal cell carcinoma: expert consensus","volume":"9","author":"Escudier","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1510","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.11.002_bib1515","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1520","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","article-title":"Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?","volume":"23","author":"Santini","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.phrs.2013.11.002_bib1525","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: justum pretium \u2013 the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T21:08:11Z","timestamp":1647464891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661813001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":305,"alternative-id":["S1043661813001771"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2013.11.002","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ErbB\/HER family of protein-tyrosine kinases and cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2013.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}